Published on in Vol 7 (2023)
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/53619, first published
.
Journals
- Silvestrini B, Silvestrini M, Choubey M. Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic. Journal of Obesity 2024;2024:1 View
- Johnson H, Huang D, Liu V, Ammouri M, Jacobs C, El-Osta A. Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study. Journal of Medical Internet Research 2025;27:e69466 View
- Febrey S, Nunns M, Buckland J, Abbott R, Bethel A, Whear R, Boddy K, Melendez‐Torres G, Coon J, Shaw L. What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review. Health Expectations 2025;28(2) View
- Kushner R, Johansen O, Araujo Torres K, Phan T, Marczewska A. Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects. Obesities 2025;5(2):29 View